QPPV.COM KNOWLEDGE ASSESSMENT

Dapagliflozin: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Dapagliflozin: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A company carries forward a diabetes-only safety assessment for dapagliflozin after use expands into heart failure and CKD. What is the main pharmacovigilance weakness?
Question 2 of 10 A case report contains ketones in urine but no clinical diagnosis or supporting metabolic assessment. How should the event be represented?
Question 3 of 10 A patient taking dapagliflozin develops nausea, ketones and metabolic acidosis during acute illness, but blood glucose is not markedly elevated. What is the most appropriate clinical interpretation?
Question 4 of 10 A pharmacovigilance case records only that 'dapagliflozin caused a fall in eGFR.' Which additional information would most improve clinical evaluation?
Question 5 of 10 What is the correct interpretation of DECLARE–TIMI 58 with respect to major adverse cardiovascular events (MACE)?
Question 6 of 10 A clinician argues that dapagliflozin should not be considered for a patient with heart failure who does not have diabetes. Which interpretation best reflects the article?
Question 7 of 10 Which statement best describes hypoglycaemia risk with dapagliflozin?
Question 8 of 10 Which description best explains how dapagliflozin lowers glucose?
Question 9 of 10 Which combination of circumstances would be most relevant when evaluating a suspected dapagliflozin-associated ketoacidosis case?
Question 10 of 10 A patient taking dapagliflozin and a diuretic becomes hypotensive and dehydrated during an intercurrent illness. Which interpretation is most appropriate?

Select an answer to continue.

QPPV.com